To validate these findings, we used larger datasets from The Cancer Genomic Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, which confirmed the significant upregulation of SLC5A3 levels in PAAD tumor tissues compared to those in normal tissues (Fig. 1D) [29–31]. This evidence concerns the gene SLC5A3 and pancreatic adenocarcinoma.